Download Files:
Tildacerfont
$200 – $4,500
Products Details
Product Description
– Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia[1].
Web ID
– HY-113603
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C20H26ClN5OS
References
– [1]Prete A, et al. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur J Endocrinol. 2021;186(1):R1-R14. Published 2021 Nov 30.
CAS Number
– 1014983-00-6
Molecular Weight
– 419.97
Compound Purity
– 98.25
SMILES
– CCC(CC)C1=CC(C)=NC2=C(C(C)=NN12)C3=C(N=C(S3)N4CCOCC4)Cl
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : 10 mg/mL (ultrasonic)
Target
– CRFR
Isoform
– CRFR1
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
